Toru Sugiyama

10PUBLICATIONS
78CO-AUTHORS
Oncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Nov 26, 2025
Prognostic impact of lymphadenectomy in patients with advanced ovarian clear cell carcinoma: an ancillary analysis of the JGOG3017-A4 study.

Satoe Fujiwara, Muneaki Shimada, Yuri Ito

|Sep 09, 2024
Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study.

Daisuke Aoki, Tsutomu Tabata, Satoshi Yanagida

|Jun 27, 2022
Incidence of fistula occurrence in patients with cervical cancer treated with bevacizumab: data from real-world clinical practice.

Toru Sugiyama, Noriyuki Katsumata, Takafumi Toita

|Sep 02, 2021
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).

Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata

|Dec 16, 2020
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.

Aikou Okamoto, Eiji Kondo, Toshiaki Nakamura

|Nov 13, 2020
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.

Takashi Motohashi, Akira Yabuno, Hiroshi Michimae

Pageof 2

Frequent Collaborators

5 joint publications

Daisuke Aoki

5 joint publications

Eiji Kondo

4 joint publications

Aikou Okamoto

4 joint publications

Tsutomu Tabata